INBX Inhibrx Biosciences, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Inhibrx Biosciences, Inc. (INBX) SEC EDGAR filings in 2026, including the most recent 10-K annual report filed on March 19, 2026, a 10-Q quarterly report filed on May 14, 2026, an 8-K current report filed on July 16, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Inhibrx Biosciences, Inc. (INBX) (SEC CIK 2007919), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
Go deeper on Inhibrx Biosciences, Inc.
Ask AI about INBX filings. Chat with the 10-K, 10-Q, and 8-K for instant answers on financials, risks, and guidance.
Track institutional money. See which funds are building or cutting INBX positions, quarter over quarter.
Catch cross-signals. Spot when insider buying, fund accumulation, and activist stakes line up on INBX.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Inhibrx Biosciences, Inc. (INBX) 8-K current reports disclosing material events.
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Jul 16, 2026 | - | - | - |
8-K | Jun 15, 2026 | - | - | - |
8-K | Jun 3, 2026 | - | - | |
10-Q | May 14, 2026 | Mar 31, 2026 | - | |
8-K | May 14, 2026 | - | - | |
8-K | May 11, 2026 | - | - | |
8-K | Apr 21, 2026 | - | - | - |
8-K | Mar 19, 2026 | - | Analysis | - |
10-K | Mar 19, 2026 | Dec 31, 2025 | - | |
8-K | Feb 23, 2026 | - | Analysis | - |
8-K | Dec 16, 2025 | - | - | |
10-Q | Nov 14, 2025 | Sep 30, 2025 | - | |
10-Q | Aug 13, 2025 | Jun 30, 2025 | - | |
10-Q | May 14, 2025 | Mar 31, 2025 | - | |
10-K | Mar 17, 2025 | Dec 31, 2024 | - | |
10-Q | Nov 14, 2024 | Sep 30, 2024 | - | |
SC 13G | Nov 14, 2024 | - | - | |
10-Q | Aug 13, 2024 | Jun 30, 2024 | - | |
SC 13G | Jun 7, 2024 | - | - | |
SC 13D | Jun 3, 2024 | - | - | |
SC 13D | Jun 3, 2024 | - | - | |
SC 13G | May 31, 2024 | - | - |
13F Fund Holdings: Quarterly Trend
Latest: Q1 2026Aggregate INBX share value held by 13F filers tracked by SignalX, by quarter.
- State Street Corp+175.9K (+47%)
- Morgan Stanley+95.3K (+8%)
- Millennium Management+51.9K (+19%)
- BlackRock+21.5K (+3%)
- Citigroup+6.8K (+12%)
- Citadel Advisors LLC136.9K (-66%)
- D.E. Shaw & Co44.7K (-31%)
- Bank of America Corp36.4K (-53%)
- Wells Fargo & Co6.9K (-64%)
- Goldman Sachs Group5.5K (-3%)
- Franklin Resources+34.2K
- Coatue Management+5.5K
- Fifth Third Bancorp+21
- Vanguard Group Inc−623.1K
- Invesco Ltd−112.4K
- JPMorgan Chase & Co−17.1K
- Ameriprise Financial−3.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 130 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe.
Frequently Asked Questions
What are the latest INBX SEC filings in 2026?
Inhibrx Biosciences, Inc. (INBX) has filed a 10-K annual report on March 19, 2026, a 10-Q quarterly report on May 14, 2026, an 8-K current report on July 16, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did INBX file its most recent 10-K annual report?
Inhibrx Biosciences, Inc. (INBX) filed its most recent 10-K annual report on March 19, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view INBX 10-Q quarterly reports?
Inhibrx Biosciences, Inc. (INBX)'s most recent 10-Q quarterly report was filed on May 14, 2026. SignalX displays every INBX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has INBX filed recently?
Inhibrx Biosciences, Inc. (INBX)'s most recent 8-K was filed on July 16, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find INBX insider trading activity (Form 4)?
SignalX aggregates every INBX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does INBX file with the SEC?
Inhibrx Biosciences, Inc. (INBX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new INBX filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Inhibrx Biosciences, Inc. (INBX).
What is INBX's SEC CIK number?
Inhibrx Biosciences, Inc. (INBX)'s SEC CIK (Central Index Key) number is 2007919. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 2007919 to look up all INBX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Stay on top of Inhibrx Biosciences, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 22+ filings.